My watch list  

5-alpha-reductase inhibitor

5α-reductase inhibitors (or 5-alpha-reductase inhibitors) are a group of drugs with antiandrogenic activity, used in the treatment of benign prostatic hyperplasia and androgenic (or androgenetic) alopecia. These drugs decrease the levels of available 5α-reductase prior to testosterone binding with the enzyme, thus reducing levels of dihydrotestosterone that derives from such a bond.


Clinical use


5α-reductase inhibitors are clinically used in the treatment of conditions which are exacerbated by dihydrotestosterone. Specifically, these indications may include: (Rossi, 2004)

Adverse drug reactions

Adverse drug reactions (ADRs) experienced with 5α-reductase inhibitors are generally dose-dependent. Common ADRs include impotence, decreased libido, decreased ejaculate volume. Rare ADRs include: breast tenderness and enlargement, and allergic reaction. (Rossi, 2004)


The enzyme 5α-reductase is involved in the conversion of testosterone to the active form dihydrotestosterone by reducing the Δ4,5 double-bond. In benign prostatic hyperplasia, dihydrotestosterone acts as a potent cellular androgen and promotes prostate growth - inhibiting the enzyme reduces the excessive prostate growth. In alopecia, pattern-baldness is one of the effects of androgenic receptor activation. Reducing the levels of dihydrotestosterone thus reduces alopecia.


  • finasteride (Proscar, Propecia)
  • dutasteride (Avodart)
  • FCE 28260, an experimental compound


This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "5-alpha-reductase_inhibitor". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE